OptiNose, Inc. (NASDAQ:OPTN) is expected to report second quarter earnings results, before market open, on Tuesday 4th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.56 per share.
Looking ahead, the full year loss are expected at $ 2.16 per share on the revenues of $ 51.97 million.
Previous Quarter Performance
OptiNose, Inc. unveiled loss for the first quarter of $ 0.63 per share, from the revenue of $ 7.06 million. The quarterly revenues raised 57.59 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.65 per share from $ 7.84 million in revenue. The bottom line results beat street analysts by $ 0.02 or 3.08 percent, at the same time, top line results fell short of analysts by $ 0.78 million or 9.95 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of OptiNose, Inc.
Stock Performance
According to the previous trading day, closing price of OPTN was $ 5.71, representing a 74.09 % increase from the 52 week low of $ 3.28 and a 51.03 % decrease over the 52 week high of $ 11.66.
The company has a market capital of $ 262.12 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”OPTN” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
OptiNose, Inc. will be hosting a conference call at 8:00 AM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.optinose.com
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.
